Formulation, characterization, and evaluation of doxorubicin-loaded cubosome as a cytotoxic potentiator against HCT-116 colorectal cancer cells
By: Almoshari, Yosif
.
Contributor(s): Mohammad Intakhab Alam
.
Publisher: Karnataka Association of Pharmaceutical Teachers of India (APTI) 2022Edition: Vol.56(3), Jul-Sep.Description: 723-731p.Subject(s): PHARMACEUTICS![](/opac-tmpl/bootstrap/images/filefind.png)
Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
---|---|---|---|---|---|---|
![]() |
School of Pharmacy Archieval Section | Not for loan | 2022-1379 |
Background: Colorectal cancer (CRC) has grown to be the world’s fourth-biggest cause
of cancer-related mortality. It is critical to identify more effective treatment options for
it. Objectives: Doxorubicin a potent antineoplastic agent is widely used but has severe
adverse effects. Therefore, our objective is to use cubosome as an efficient drug delivery
system to reduce the off-target effects and increase the cytotoxic effects in CRC cells.
Materials and Methods: Pluronic F127-Based Cubosomes were prepared by low energy
stirring method and loaded with doxorubicin. Physicochemical characteristics were
studied using X-ray diffraction, dynamic light scattering, microscopic techniques, FTIR
UV spectrophotometer, and entrapment efficiency.
In vitro activity of doxorubicin-loaded
cubosomes was studied on HCT-116 cells. Results: The prepared cubosomes have the
required nano-size and the FTIR results showed the presence of both doxorubicin and
Pluronic F-127. The entrapment efficiency of doxorubicin was high too. DOX-CBs have
a better cytotoxic effect and induced ROS and reduced NO levels in HCT-116 cells.
Conclusion: The obtained results show that doxorubicin-loaded cubosomes can be used
to increase the cytotoxic effect in CRC cells and can be used with other chemotherapeutic
agents.
There are no comments for this item.